Andrich, D. (2011). Rating scales and Rasch measurement. Expert Review of Pharmacoeconomics & Outcomes Research, 11(5), 571-585.
Bérard, C., Payan, C., Hodgkinson, I., Fermanian, J., & MFM Collaborative Study Group. (2005). A motor function measure scale for neuromuscular diseases. Construction and validation study. Neuromuscular disorders, 15(7), 463-470.
Bérard C, Girardot F, Payan C. User’s Manual: MFM-32 & MFM-20, Accessible at https://mfm-nmd.org/get-a-user-manual/?lang=en (Accessed 29 March 2021).
Bolognani, F., del Valle Rubido, M., Squassante, L., Wandel, C., Derks, M., Murtagh, L., ... & Fontoura, P. (2019). A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder. Science Translational Medicine, 11(491).
Centre for Evidence-Based Medicine (CEBM), Number Needed to Treat (NNT), Available at https://www.cebm.ox.ac.uk/resources/ebm-tools/number-needed-to-treat-nnt (Accessed 29 March 2021).
Chatham, C. H., Taylor, K. I., Charman, T., Liogier D'Ardhuy, X., Eule, E., Fedele, A., ... & Bolognani, F. (2018). Adaptive behavior in autism: Minimal clinically important differences on the Vineland‐II. Autism Research, 11(2), 270-283.
Citrome, L., & Ketter, T. A. (2013). When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed. International Journal of Clinical Practice, 67(5), 407-411.
Cohen, J. (1988). Statistical power analysis for the behavioural sciences. Hillsdale, NJ: Laurence Erlbaum Associates.
Coon, C. D., & Cook, K. F. (2018). Moving from significance to real-world meaning: methods for interpreting change in clinical outcome assessment scores. Quality of Life Research, 27(1), 33-40.
Copay, A. G., Subach, B. R., Glassman, S. D., Polly Jr, D. W., & Schuler, T. C. (2007). Understanding the minimum clinically important difference: a review of concepts and methods. The Spine Journal, 7(5), 541-546.
Duong, T., Braid, J., Staunton., H et al. (2021). Understanding the relationship between the 32-item motor function measure and daily activities from an individual with spinal muscular atrophy and their caregivers’ perspective: a two-part study. In Press.
FDA, U.S. Food and Drug Administration. (2018, October 15-16). Patient-Focused Drug Development Guidance Public Workshop (PFDD3). Methods to Identify What is Important to Patients & Select, Develop or Modify Fit-for-Purpose Clinical Outcomes Assessments, Available at https://www.fda.gov/media/116277/download (Accessed 29 March 2021)
FDA, U.S. Food and Drug Administration. (2019, December 6). Patient-Focused Drug Development Guidance Public Workshop (PFDD4). Incorporating Clinical Outcome Assessments into Endpoints for Regulatory Decision-Making, Available at https://www.fda.gov/media/132505/download (Accessed 29 March 2021).
Guralnik, J., Bandeen-Roche, K., Bhasin, S. A., Eremenco, S., Landi, F., Muscedere, J., ... & Vellas, B. (2020). Clinically meaningful change for physical performance: perspectives of the ICFSR Task Force. The Journal of Frailty & Aging, 9(1), 9-13.
Hobart, J., & Cano, S. (2009). Improving the evaluation of therapeutic interventions in multiple sclerosis: the role of new psychometric methods. Health Technol Assess,13(12).
IQWIG, Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (2020, November 5), Allgemeine Methoden, Available at https://www.iqwig.de/methoden/allgemeine-methoden_version-6-0.pdf?rev=180500 (Accessed 29 March 2021).
Lievens, Y., Audisio, R., Banks, I., Collette, L., Grau, C., Oliver, K., ... & Aggarwal, A. (2019). Towards an evidence-informed value scale for surgical and radiation oncology: a multi-stakeholder perspective. The Lancet Oncology, 20(2), e112-e123.
Lord, C., & Jones, R. M. (2012). Annual Research Review: Re‐thinking the classification of autism spectrum disorders. Journal of Child Psychology and Psychiatry, 53(5), 490-509.
NICE, National Institute for Health and Care Excellence, Glossary - Number needed to treat, Available at https://www.nice.org.uk/glossary?letter=n (Accessed 29 March 2021).
Petrillo, J., Cano, S. J., McLeod, L. D., & Coon, C. D. (2015). Using classical test theory, item response theory, and Rasch measurement theory to evaluate patient-reported outcome measures: a comparison of worked examples. Value in Health, 18(1), 25-34.
Powers III, J. H., Patrick, D. L., Walton, M. K., Marquis, P., Cano, S., Hobart, J., ... & Burke, L. B. (2017). Clinician-reported outcome assessments of treatment benefit: report of the ISPOR clinical outcome assessment emerging good practices task force. Value in Health, 20(1), 2-14.
Rai, S. K., Yazdany, J., Fortin, P. R., & Aviña-Zubieta, J. A. (2015). Approaches for estimating minimal clinically important differences in systemic lupus erythematosus. Arthritis Research & Therapy, 17(1), 1-8.
Sparrow, S. S., Cicchetti, D., & Balla, D. A. (2005). Vineland Adaptive Behavior Scales-2nd Edition Manual. Minneapolis, MN: NCS Pearson, Inc.
Trundell, D., Le Scouiller, S., Gorni, K., Seabrook, T., & Vuillerot, C. (2020). Validity and reliability of the 32-item motor function measure in 2-to 5-year-olds with neuromuscular disorders and 2-to 25-year-olds with spinal muscular atrophy. Neurology and Therapy, 9(2), 575-584.
Trundell D, Le Scouiller S, Servais L et al. Using Rasch analysis to estimate thresholds associated with gain/loss of daily function on the Motor Function Measure (MFM). Poster presented at the Cure SMA Researcher Meeting, Poster at 23rd International SMA Research Meeting, Anaheim, CA, June 28-July 1, 2019.
Trundell, D., Scouiller, S., & Servais, L. (2021). Using Rasch analysis to estimate thresholds associated with gain or loss of daily activities on the 32-item Motor Function Measure (MFM32). Manuscript submitted for publication.
Vuillerot, C., Payan, C., Iwaz, J., Ecochard, R., Bérard, C., & MFM Spinal Muscular Atrophy Study Group. (2013). Responsiveness of the motor function measure in patients with spinal muscular atrophy. Archives of Physical Medicine and Rehabilitation, 94(8), 1555-1561.